Kala Bio Chases 'Palantir For Biotech' Dream With New AI Platform

Kala Bio Inc. (NASDAQ:KALA) shares are up during Wednesday’s premarket session as the company is preparing to ship its first commercial AI product in approximately 14 days.

Kala Bio Ready to Ship First AI Product

Kala Bio announced that it is ready to ship its first commercial AI product, which is expected to transform the company’s operations and potentially the biotech industry.

The product is set to launch in about 14 days, marking a significant milestone for the company.

Targets $180 Billion Agentic AI Healthcare Revolution

The move transforms Kala Bio from a clinical-stage biotech into a dual-engine growth story powered by both a proprietary drug pipeline and a scalable AI platform targeting the $180+ billion AI-in-healthcare market by 2030.

Kala is positioning itself as the go-to AI infrastructure partner for the biotech industry, no longer a single-asset bet, but a platform company with the potential to serve an entire industry.

The company said the opportunity comes as the world’s 20 largest pharmaceutical companies collectively spent about $167 billion on research and development in 2024, while AI adoption in drug discovery remains in its early stages.

Seeks To Build Palantir For Biotech

Kala Bio, in a press release on Wednesday, said it is building the Palantir for biotech.

Just as Palantir built a $250+ billion company by helping governments and enterprises make sense of massive data, Kala is doing the same for the biotech and pharmaceutical industry.

The penny stock seeks to leverage its Researgency.ai platform, deploying purpose-built AI agents that handle the repetitive, high-stakes jobs that slow drug companies down faster, cheaper, and with fewer errors than humans.

Researgency Licensing Agreement

Last week, Kala entered a platform development and exclusive license agreement with 2624465 Ontario Inc., operating as Younet AI, for a proprietary AI research platform called Researgency.

The agreement grants KALA exclusive worldwide rights to deploy the platform in the biotechnology field for an initial 12-month term, with options for renewal.

Failed Eye Disease Study

Kala Bio, in September 2025, halted development of its experimental treatment for a specific eye condition.

The company announced that its CHASE Phase 2b trial of KPI-012 for persistent corneal epithelial defect (PCED) did not meet the primary endpoint of complete healing of PCED as measured by corneal fluorescein staining.

The CHASE trial also failed to achieve statistical significance for key secondary efficacy endpoints and did not show any meaningful difference between either KPI-012 treatment arm and the placebo arm.

KALA BIO Shares Surge 63.05% in Premarket

KALA Price Action: Kala Bio shares were up 63.05% at $0.47 during premarket trading on Wednesday, according to Benzinga Pro data.

Image via Shutterstock